Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alanine ethyl ester butyrate is a bioactive ionic liquid (BIL) composed of an L-alanine ethyl ester cation and a butyrate anion. It is primarily utilized in pharmaceutical research as a multifunctional drug delivery vehicle and therapeutic agent. Developed to address the solubility and bioavailability challenges of lipophilic compounds, such as the anti-cancer agent glycyrol, this ionic liquid functions as both a specialized solvent and a bioactive component. The butyrate moiety provides intrinsic therapeutic activity by acting as a histone deacetylase (HDAC) inhibitor and an agonist of free fatty acid receptors (FFAR2/FFAR3), which collectively promote apoptosis and inhibit proliferation in malignant cells. Research has demonstrated its potential in enhancing the oral delivery and synergistic anti-tumor efficacy of co-administered drugs, particularly in models of colorectal cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alanine ethyl ester butyrate.